Phaseline

Targets › GFRAL

GFRAL (GDNF family receptor alpha-like): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Brainstem-restricted receptor for GDF15 hormone, which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses. The aversive response is both required to reduce continuing exposure to those stresses at the time of exposure and to promote avoidance behavior in the future. (UniProt, Q6UXV0)

Open in Phaseline: the race on GFRAL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai JMT-BioJMT203 Injection
anti-GFRAL monoclonal antibody
GFRALPhase 1Non Small Cell Lung CancerAug 2027

Conditions

Non Small Cell Lung Cancer (1)

Modalities

small molecule (1)

Companies

Shanghai JMT-Bio (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.